Study Evaluating the Safety of Enbrel (Etanercept)

N/ACompletedNCT00683384

Wyeth is now a wholly owned subsidiary of Pfizer93 enrolled

Overview

The purpose of this study is to collect post-marketing information on the safety of Enbrel in Filipino patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Arthritis, Psoriatic

Interventions

Etanercept (Enbrel)DRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * All patients from the study center who received or will receive at least one dose of Enbrel according to the approved product indication. Exclusion Criteria: * Previously discontinued Enbrel therapy due to significant safety concern.

Locations (1)

Unnamed facility

Metro Manila, Philippines

Outcomes

Primary Outcomes

Number of Participants With Spontaneous Adverse Events Reported Until 30 Days After Each Injection

Time frame: 30 days post injection up to 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.